Anika Therapeutics (ANIK) Restructuring Costs (2013)
Anika Therapeutics (ANIK) reported Restructuring Costs of $111178.0 for Q2 2013, down 18.01% quarter-over-quarter from $135607.0 in Q1 2013.
Anika Therapeutics (ANIK) Restructuring Costs (2013) Analysis & Trends
Anika Therapeutics (ANIK) has 1 years of Restructuring Costs data on file, last reported at $111178.0 in Q2 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 111,178.00 |
| Mar 31, 2013 | 135,607.00 |